This article was originally published on Microdose and appears here with permission.
PharmaTher is one of the psychedelic medicine industry’s best kept secrets. With several Phase 2 trials in the works, a growing pipeline of both drug development and delivery methods, and a solid working relationship with the FDA (they’ve already received Orphan Drug Designation from the FDA for one of their programs) — PharmaTher seems well-positioned to corner the ketamine segment of the market.
